financetom
Business
financetom
/
Business
/
Vista Outdoor Says Kinetic Group Purchase Price Raised by Czechoslovak Group to $2.1 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vista Outdoor Says Kinetic Group Purchase Price Raised by Czechoslovak Group to $2.1 Billion
Jul 8, 2024 4:20 AM

07:03 AM EDT, 07/08/2024 (MT Newswires) -- Vista Outdoor ( VSTO ) said Monday that it entered an amendment to the merger agreement with Czechoslovak Group, increasing the purchase price for The Kinetic Group business by $100 million to $2.1 billion.

The amendment also increases the cash consideration payable to Vista Outdoor ( VSTO ) stockholders by $3 per share of Vista Outdoor ( VSTO ) common stock to $21 in cash, the company said.

The Vista Outdoor ( VSTO ) board unanimously reaffirmed the recommendation that its stockholders vote in favor of the transaction. A special meeting of stockholders to vote on the merger is scheduled for July 23.

Meanwhile, the board unanimously rejected MNC Capital's final indication as "inadequate and opportunistic", saying it undervalues Vista Outdoor ( VSTO ) as a whole, especially the Revelyst business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boralex Q3 Loss Widens on Weak Power Prices Despite Higher Output
Boralex Q3 Loss Widens on Weak Power Prices Despite Higher Output
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Boralex ( BRLXF ) on Friday said its third-quarter loss widened as revenue fell as weaker prices offset higher power production. The renewable-power company said it lost $27 million, or $0.26 per share, compared to a loss of $14 million, or $0.13, in the year-prior quarter. The result lagged the FactSet consensus estimate...
Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug
Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday that new long-term data on its drug Livdelzi showed consistent efficacy and safety in treating primary biliary cholangitis, including in patients who switched from obeticholic acid, with sustained improvements in liver stiffness over three years. The company said the long-term study showed that 67% of participants...
Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study
Regeneron, Sanofi Say Dupixent for Allergic Fungal Rhinosinusitis Met Primary Endpoint in Phase 3 Study
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that Dupixent (dupilumab) for treatment of allergic fungal rhinosinusitis in adults and children aged six years and older met all primary and secondary endpoints in a phase three study. The study showed that Dupixent significantly reduced key nasal signs and symptoms...
Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares
Strategy Prices IPO of Euro-Denominated Perpetual Preferred Shares
Nov 7, 2025
08:34 AM EST, 11/07/2025 (MT Newswires) -- Strategy (MSTR) said Friday it priced an initial public offering a day earlier of about 7.8 million shares of 10% series A perpetual preferred stock at 80 euros ($92.48) each. The issuance and sale of the stock under the ticker STRE is scheduled to settle on Nov. 13, the company said. Strategy said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved